Fig. 5

Involvement of K⁺-channels and cAMP/cGMP to the vasorelaxant effect of imatinib. a PA (100 nM ET-1): (●) imatinib (n = 5); () 10 μM glibenclamide / imatinib (n = 6); (⃝) 10 μM glibenclamide (n = 7); b PA (100 nM ET-1): (●) imatinib (n = 5); () 100 nM iberiotoxin / imatinib (n = 4)(⃝) 100 nM iberiotoxin (n = 5); c PA (100 nM ET-1): (●) imatinib (n = 6); () 5 mM 4-AP / imatinib (n = 6) (⃝) 5 mM 4-AP (n = 6). d Effect of imatinib on cAMP. e Effect of imatinib on cGMP. a-c EC₅₀ values were calculated using the standard 4-paramter logistic non-linear regression model. If EC₅₀ values were not calculable (controls with K⁺-channel inhibitors), a LMM was applied. d, e Statistics were performed by the Mann-Whitney U test. P < 0.05 are considered as significant: ^* p < 0.05, ^** p < 0.01 and ^*** p < 0.001